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Amplification: Identification of Urinary Substances
Associated with Inhibition and Removal
of Inhibitory Activity
J. MAHONY,1,2,3* S. CHONG,1 D. JANG,1 K. LUINSTRA,1 M. FAUGHT,1 D. DALBY,3
J. SELLORS,3,4 AND M. CHERNESKY1,2,3,5
Regional Virology and Chlamydiology Laboratory,1 Departments of Pathology,2 Pediatrics,5 and Family Medicine,4
McMaster University, and FSORC, St. Joseph’s Hospital,3 Hamilton, Ontario, Canada
Received 3 April 1998/Returned for modification 29 June 1998/Accepted 7 August 1998

The presence of endogenous amplification inhibitors in urine may produce false-negative results for the
detection of Chlamydia trachomatis nucleic acids by tests such as PCR, ligase chain reaction (LCR), and
transcription-mediated amplification (TMA). Consecutive urine specimens from 101 pregnant women and 287
nonpregnant women submitted for urinalysis were processed for C. trachomatis detection. Aliquots were spiked
with the equivalent of one C. trachomatis elementary body and were tested by three commercial assays:
AMPLICOR CT/NG, Chlamydia LCX, and Chlamydia TMA. The prevalence of inhibitors resulting in complete
inhibition of amplification was 4.9% for PCR, 2.6% for LCR, and 7.5% for TMA. In addition, all three assays
were partially inhibited by additional urine specimens. Only PCR was more often inhibited by urine from
pregnant women than by urine from nonpregnant women (9.9 versus 3.1%; P 5 0.011). A complete urinalysis
including dipstick and a microscopic examination was performed. Logistic regression analysis revealed that
the following substances were associated with amplification inhibition: beta-human chorionic gonadotropin
(odds ratio [OR], 3.3) and crystals (OR, 3.3) for PCR, nitrites for LCR (OR, 14.4), and hemoglobin (OR, 3.3),
nitrites (OR, 3.3), and crystals (OR, 3.3) for TMA. Aliquots of each inhibitory urine specimen were stored at
4 and 270°C overnight or were extracted with phenol-chloroform and then retested at dilutions of 1:1, 1:4, and
1:10. Most inhibition was removed by storage overnight at 4 or 270°C and a dilution of 1:10 (84% for PCR,
100% for LCR, and 92% for TMA). Five urine specimens (three for PCR and two for TMA) required
phenol-chloroform extraction to remove inhibitors. The results indicate that the prevalence of nucleic acid
amplification inhibitors in female urine is different for each technology, that this prevalence may be predicted
by the presence of urinary factors, and that storage and dilution remove most of the inhibitors.
hospital clinical chemistry laboratory for routine urinalysis, we
found that 9% of urine specimens from men and 18% of urine
specimens from women contained PCR inhibitors (4). These
observations provided the rationale for a prospective study to
determine (i) the prevalence of inhibitors in urine specimens to
be tested by PCR, LCR, and TMA; (ii) the urinary components
associated with amplification inhibition; and (iii) treatment
procedures which might remove inhibitors from urine.

Nucleic acid amplification (NAA) techniques such as PCR,
ligase chain reaction (LCR), and transcription-mediated amplification (TMA) have greatly improved our ability to diagnose Chlamydia trachomatis infections, and in recent years,
they have been successfully applied to first-void urine specimens. NAA testing of first-void urine specimens has usually
detected as many positive patients as testing of urethral or
endocervical swabs by cell culture or antigen testing (1–3, 5, 6,
8, 10, 12, 15), but most of these studies have also revealed that
none of the amplification tests is 100% sensitive. While the
majority of processed specimens are amplifiable, some contain
substances that inhibit NAA, thereby giving false-negative results, even if the specimen contains C. trachomatis nucleic acid.
In a study comparing PCR and LCR testing of 767 female
urine specimens, we observed 15 (1.9%) urine specimens
which were positive by one test but not by the other, a discrepancy which could be explained by the presence of inhibitory
substances (3). In a study of 200 urine specimens sent to a

MATERIALS AND METHODS
Specimens. This laboratory-based study tested 388 freshly collected urine
specimens submitted for routine urinalysis to clinical chemistry laboratories in
three university teaching hospitals. Urine specimens (20 to 50 ml) were obtained
from 101 pregnant women and 287 nonpregnant women between 15 and 40 years
of age. The specimens were transported by courier at room temperature each
morning, together with a printed copy of the urinalysis report, to the Regional
Virology and Chlamydiology Laboratory at St. Joseph’s Hospital, aliquoted by
one technologist, and tested blindly on the same day by three C. trachomatis
nucleic acid detection assays.
Urinalysis. A complete urinalysis including dipstick and microscopic examination was performed for each urine specimen. Fresh urine specimens were
tested for the presence of leukocytes, nitrites, protein, blood, ketone, and glucose, and their specific gravities and pHs were measured with the Multistix 8 SG
dipstick (Bayer Inc., Etobicoke, Ontario, Canada). The dipstick was read, according to the manufacturer’s instructions, with an automated urine chemistry
analyzer (Clinitex 2001; Bayer Corp.). Positive urinary protein results from the
dipstick were confirmed by a semiquantitative sulfosalyic acid test, which simply
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FIG. 1. Algorithm showing procedures used to study specimens containing inhibitors of PCR, LCR, and TMA. Complete Inhibition1, signal below the cutoff of
positivity for the test; Phenol-chloroform2, nucleic acid precipitated overnight.

involved the mixing of 1.0 ml of centrifuged urine to 3.0 ml of 3% sulfosalyic acid.
After 5 min, the degree of turbidity caused by the precipitation of denatured
protein was observed and was graded from negative to 41. For microscopic
examination of the urine, 10- to 15-ml aliquots were spun at 1,000 rpm for 5 min.
A drop of the resulting sediment was transferred to a microscope slide. Examination for epithelial cells, erythrocytes and leukocytes, mucus, yeast, bacteria,
casts, and various types of crystals (oxalate, phosphate, urate) was done under
both low and high magnifications of the light microscope by trained technicians
using standard criteria (17).
Detection of amplification inhibitors by spiking experiments. C. trachomatis
L2 434 was propagated in McCoy cells, and elementary bodies (EBs) were
purified by differential centrifugation as described previously (3). EBs were
resuspended in phosphate-buffered saline and counted by direct fluorescentantibody (DFA) staining with monoclonal antibodies specific for major outer
membrane proteins (Syva Microtrak, San Jose, Calif.). A serial dilution of C.
trachomatis containing approximately one EB determined by DFA staining was
tested in triplicate by AMPLICOR CT/NG (Roche Molecular Systems, Branchburg, N.J.), Chlamydia LCX (Abbott Diagnostics, North Chicago, Ill.), and
Chlamydia TMA (Gen-Probe, San Diego, Calif.) to ensure that a spike of one
EB would generate a positive signal in each test. This dilution gave positive
readings in all three tests and was used to spike aliquots of urine specimens.
Spiked and unspiked aliquots of urine were tested to detect inhibition of amplification. Complete inhibition was defined as a reduction in signal below the
manufacturer’s cutoff. Partial inhibition was defined arbitrarily as a reduction in
signal greater than 20% but less than 100%.
Removal of inhibitory activity. Only urine specimens showing complete inhibition were used to evaluate methods for removing inhibitory activity. Complete
inhibition was defined as a signal dropping below the positive cutoff for each test.
Urine specimens showing complete inhibition were retested by the algorithm
shown in Fig. 1. Aliquots of urine were stored overnight at 4 and 270°C, while
a third aliquot was extracted with phenol-chloroform and was allowed to precipitate overnight. Aliquots of urine and extracted nucleic acid were then retested undiluted and at dilutions of 1:4 and 1:10.
PCR. Aliquots of urine unspiked and spiked with C. trachomatis were tested by
the AMPLICOR CT/NG test. The spike contained one EB of C. trachomatis,
equivalent to approximately 10 target molecules for PCR. AMPLICOR CT/NG
was performed according to the manufacturer’s instructions. Briefly, 0.5 ml of
urine was centrifuged at 16,000 3 g for 5 min at room temperature. The pellet
was resuspended in 0.25 ml of lysis buffer, vortexed, and incubated for 15 min at
room temperature. An equal volume of specimen diluent buffer was added, and
the tubes were vortexed and centrifuged at 16,000 3 g for 10 min. A 50-ml aliquot
of the supernatant was used for amplification. Urine specimens that demonstrated complete inhibition were retested following overnight storage at 4 and

270°C and after extraction with phenol-chloroform according to the algorithm
(Fig. 1).
LCR. The Chlamydia LCX assay was performed according to the manufacturer’s instructions. One milliliter of urine was centrifuged at 16,000 3 g for 15
min, and the pellet was resuspended in 1 ml of urine resuspension buffer. The
tubes were placed in a heating block at 95°C for 15 min. After cooling to room
temperature, 0.2 ml was added to the unit dose and the samples were amplified
and read on the LCX instrument.
TMA. The Gen-Probe Chlamydia TMA assay was performed according to the
manufacturer’s instructions. Briefly, 1.5 ml of urine was incubated for 10 min at
37°C followed by centrifugation at 8,000 3 g for 5 min. The supernatant was
decanted, and the pellet was resuspended in 0.2 ml of specimen diluent buffer.
Twenty five microliters of amplification reagent was added to separate tubes,
followed by the addition of 200 ml of oil reagent. Fifty microliters of processed
specimen was pipetted under the oil, and the tubes were incubated for 10 min at
95°C in a heating block. The tubes were cooled to 42°C, and 25 ml of enzyme
reagent was added and the mixture was incubated for 1 h at 42°C. Twenty
microliters of termination reagent was added, and the mixture was incubated for
10 min at 42°C. The probe was added and the tubes were incubated for 15 min
at 60°C. The selection reagent was added and the tubes were incubated for 10
min at 60°C prior to the hybridization protection assay, which was performed
according to the instructions in the manufacturer’s package insert.
Data analysis. Variables and outcome predictors were recoded prior to analysis to indicate the absence or presence of urinary components. Both univariate
and multivariate analyses were performed to determine which urinary components were associated with complete amplification inhibition. Univariate analysis
was carried out by the continuity-corrected chi-square test. For multivariate
analysis, forward logistic regression modeling was performed with SPSS software
(version 7.0). Type I (alpha) error rate was set at 0.05 (two tailed for all analyses).

RESULTS
A total of 388 urine specimens were examined in the study;
of these, 101 were positive for beta-human chorionic gonadotropin (beta-HCG). The number of urine specimens containing inhibitors for the three assays is shown in Table 1. A total
of 27 urine specimens (7.0%) had inhibitors for PCR, 15
(3.9%) had inhibitors for LCR, and 46 (11.9%) had inhibitors
for TMA. For PCR, 19 urine specimens had complete inhibi-

3124

MAHONY ET AL.

J. CLIN. MICROBIOL.

TABLE 1. Urine specimens from pregnant and nonpregnant women showing complete or partial inhibition for PCR, LCR, or TMA tests
No. (%) of inhibitorya urine specimens
Group

PCR

Pregnant (n 5 101)
Nonpregnant (n 5 287)
Total (n 5 388)

LCR

TMA

Complete

Partial

Total

Complete

Partial

Total

Complete

Partial

Total

10 (9.9)
9 (3.1)

2 (1.9)
6 (2.1)

12 (11.9)
15 (5.2)

1 (1.0)
9 (3.1)

2 (2.0)
3 (1.0)

3 (2.9)
12 (4.2)

7 (6.9)
22 (7.7)

5 (5.0)
12 (4.1)

12 (11.9)
34 (11.8)

19 (4.9)

8 (2.1)

27 (7.0)

10 (2.6)

5 (1.3)

15 (3.9)

29 (7.5)

17 (4.4)

46 (11.9)

a

Complete inhibition was defined as a reduction in the signal to a level below the cutoff for positivity in each assay; partial inhibition was defined as greater than
20% but less than 100% of the signal achieved by the positive control spike.

tory activity, as defined by a reduction in the signal to a level
below the manufacturer’s cutoff, and 8 additional urine specimens had detectable or partial inhibitory activity, as defined by
at least a 20% reduction in the signal. Ten urine specimens
completely inhibited the LCR and 5 additional urine specimens partially inhibited the LCR. For TMA, 29 urine specimens had complete inhibitory activity and 17 specimens had
partial inhibitory activity. The percentage of urine specimens
from pregnant women with complete inhibitory activity was
slightly lower than the percentage from nonpregnant women
for both LCR (1.0 versus 3.1%) and TMA (6.9 versus 7.7%).
For PCR, 9.9 and 3.1% of urine specimens from pregnant and
nonpregnant women, respectively (P 5 0.011), had complete
inhibitory activity; for any detectable inhibitors of PCR, the
values were 11.9 and 5.2%, respectively (P 5 0.038). Inhibition
appeared to be test specific because 11 of 77 urine specimens
were inhibitory for two amplification tests, and none were
inhibitory for all three tests.
The results of a univariate analysis of urine parameters associated with complete inhibition of PCR, LCR, and TMA are
presented in Table 2. PCR inhibition was significantly associated (P , 0.05) with the presence of hemoglobin, beta-HCG,
crystals, and bacteria. The presence of glucose and nitrites was
significantly associated (P , 0.05) with LCR inhibition, while
the presence of hemoglobin, protein, ketones, nitrites, crystals,
and bacteria was associated (P , 0.05) with TMA inhibition.
When multivariate analysis was performed to determine
which substances were associated with inhibition, logistic regression modeling revealed that hemoglobin (odds ratio [OR],
3.29; P 5 0.004), nitrites (OR, 3.57; P 5 0.025), and crystals
(OR, 3.18; P 5 0.005) were associated with inhibition of TMA
(Table 3). For PCR, beta-HCG (OR, 3.43; P 5 0.038) and

crystals (OR, 3.59; P 5 0.025) were associated with inhibition,
and for LCR only nitrites were significantly associated with
inhibition (OR, 14.36; P 5 0.011).
The effects of storage at different temperatures and dilution
of the urine on the inhibitory activity are indicated in Table 4.
An insufficient volume of 5 urine specimens for TMA and 1
urine specimen for LCR left 24 and 9 urine specimens, respectively, for inhibitor removal studies. Storage overnight at 4°C
removed inhibitory substances from 8 of 19 (42.1%) specimens
for PCR, 5 of 9 (55.5%) specimens for LCR, and 19 of 24
(79.1%) specimens for TMA. Storage at 270°C similarly removed inhibitory substances from 11 of 19 (57.9%) specimens
for PCR, 4 of 9 (44.4%) specimens for LCR, and 19 of 24
(79.1%) specimens for TMA. PCR inhibitors were removed
further by dilution to 1:4 (after storage at 4 or 270°C) for
73.6% (14 of 19) of the specimens, and further dilution to 1:10
increased the proportion to 84.2% (16 of 19). Thus, 3 of 19
specimens resisted PCR inhibitor removal after storage and
dilution. Dilution of specimens with inhibitors of TMA increased the numbers rendered noninhibitory from 19 to 22,
leaving 2 of 24 persistently inhibitory urine specimens. Dilutions removed all inhibitory activity for LCR. Phenol-chloroform extraction removed the inhibitors from all urine specimens.
Because the AMPLICOR CT/NG had its own internal control, we were able to compare its ability to identify urine specimens containing PCR inhibitors. The AMPLICOR internal
control detected 13 (3.4%) urine specimens that had inhibitory
activity, while the exogenous DNA spike method detected 19
(4.9%) specimens that had completely inhibitory activity and
an additional 8 specimens that had partial inhibitory activity.

TABLE 2. Univariate analysis of urinary substances associated with complete inhibition for PCR, LCR, or TMA

Inhibitory substancea

Glucose
Hemoglobin
Protein
Ketone
Nitrites
beta-HCG
Crystals
Bacteria
a
b

PCR

LCR

No. of specimens with
complete inhibitory
activity/total no.
tested

No. of specimens with
complete inhibitory
activity/total no.
tested

Present

Absent

0/19
1/19
4/19
2/19
2/19
12/19
12/19
15/19

20/369
98/369
81/369
30/369
23/309
89/369
116/369
206/369

Pb

0.297
,0.05*
0.926
0.711
0.457
,0.001***
,0.01**
,0.05*

Present

Absent

2/10
5/10
4/10
3/10
5/10
1/10
4/10
6/10

18/378
94/378
81/378
29/378
20/378
100/378
124/378
215/378

TMA

Pb

,0.05*
0.072
0.161
0.113
,0.001***
0.242
0.633
0.844

Six other substances not statistically related were leukocytes, urates, oxalates, phosphates, casts, and yeasts.
Statistically significant differences are indicated as follows: *, P , 0.05; **, P , 0.01; ***, P , 0.001.

No. of specimens with
complete inhibitory
activity/total no.
tested
Present

Absent

2/29
10/29
11/29
6/29
6/29
7/29
17/29
24/29

18/359
83/359
74/359
26/359
19/359
94/359
111/359
197/359

Pb

0.660
,0.001***
,0.05*
,0.05*
,0.01**
0.809
,0.01**
,0.01**
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TABLE 3. Multivariate analysis of urinary substances associated
with complete inhibition of amplification by PCR, LCR, and
TMA assays
Assay

Inhibitory substancea

OR

P value

TMA

Hemoglobin
Nitrites
Crystals

3.29
3.57
3.18

0.004
0.025
0.005

PCR

beta-HCG
Crystals

3.43
3.59

0.038
0.025

LCR

Nitrites

14.36

0.011

a

Substances associated with inhibition were determined by logistic regression
analysis.

DISCUSSION
In this study of 388 urine specimens from women, the prevalence of urine specimens containing detectable inhibitors was
7.0% for PCR, 3.9% for LCR, and 11.9% for TMA. When
complete inhibition was considered, the prevalence of inhibitory urine specimens was 4.9% for PCR, 2.6% for LCR, and
7.5% for TMA. Inhibition rates were similar for urine specimens from pregnant and nonpregnant women for LCR (4.2
versus 2.9%) and TMA (11.8 versus 11.9%). For PCR, however, the proportion of inhibitory urine specimens from pregnant women was 11.9%, whereas the proportion from nonpregnant women was 5.2% (P 5 0.038). The mechanism of
PCR inhibition associated with beta-HCG is unknown.
In a letter recently published by Jensen et al. (9), the investigators reported that 15 of 1,136 urine specimens (1.3%) from
pregnant patients possibly had plasmid LCR inhibitors because
these samples which were negative by the LCX test had positive results by other tests such as DFA analysis, enzyme immunoassay, major outer membrane protein or LCR, but they
did not perform inhibitor studies. As described in another
letter (13), the investigators assumed a rate of 3% inhibition
for cervical swabs from prostitutes because of differences seen
between NAA testing and other assays, but they did not perform studies for LCR inhibitors. Berg et al. (1) used DNA
spiking and reported the presence of LCR inhibitors in 10 of
382 (2.6%) urine specimens from men attending a sexually
transmitted disease clinic. Our LCR inhibition rate of 3.9%,
which was achieved with a DNA spike equivalent to 1 EB, was
similar to the previously reported rates presented above and
TABLE 4. Removal of amplification inhibitors by
various treatments

Treatment

Dilution

No. of urine specimens rendered
noninhibitory/total no. tested (%) for the
following:
PCR

LCR

TMA

4°C overnight

1:1
1:4
1:10

8/19 (42.1)
14/19 (73.6)
16/19 (84.2)

5/9 (55.5)
7/9 (77.7)
9/9 (100)

19/24 (79.1)
22/24 (91.6)
22/24 (91.6)

270°C overnight

1:1
1:4
1:10

11/19 (57.9)
14/19 (73.6)
16/19 (84.2)

4/9 (44.4)
9/9 (100)
9/9 (100)

19/24 (79.1)
22/24 (91.6)
22/24 (91.6)

Phenol-chloroform

1:1
1:4
1:10

19/19 (100)
19/19 (100)
19/19 (100)

9/9 (100)
9/9 (100)
9/9 (100)

24/24 (100)
24/24 (100)
24/24 (100)
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particularly the 2.6% rate reported by Berg et al. (1), who used
the LCX-positive control DNA equivalent to 50 inclusionforming units.
PCR has been shown by others to have reduced sensitivity
due to inhibitors (7, 11, 18, 19). Those studies have shown that
inhibitors could be removed by dilution, freezing and thawing,
heating, or prolonged storage of the sample. Roche Molecular
Systems has developed an internal amplification control to
identify specimens containing PCR inhibitors. The internal
control can be incorporated into both the manual AMPLICOR
CT/NG test and the semiautomated COBAS AMPLICOR system (14). Specimens yielding a negative result for the internal
control are interpreted as inhibitory or nonamplifiable and
thus are not reported as negative, thereby reducing the number
of false-negative results. In our study the internal control detected 13 inhibitory specimens, while our exogenous DNA
spike method detected 19 inhibitory specimens. The discrepancies observed between the kit’s internal control and our
DNA spike for female urine specimens may be due to weakly
inhibitory specimens for which the results were below the limit
of detection for the Roche internal control. The kit internal
control has a slightly higher number of target molecules (20
copies of plasmid) compared with the one EB that we used in
our spike. In this study 15 specimens were positive for C.
trachomatis by either PCR, LCR, or TMA, but none of these
urine specimens contained inhibitors by either the DNA spike
method or the Roche internal control method. For this reason,
the efficiency of the internal control for identifying specimens
with false-negative results could not be determined. Further
studies with larger numbers of specimens will be required to
determine if the use of an internal amplification control is a
cost-effective approach for monitoring amplification inhibition.
To our knowledge this is the first study to attempt to correlate inhibition of NAA with substances found in urine. Nitrites
were associated with LCR inhibition, beta-HCG and crystals
were associated with PCR inhibition, and hemoglobin, nitrites,
and crystals were associated with TMA inhibition. These results, however, do not establish a direct causal relationship
between the implicated urinary substance and inhibition since
a small number of urine specimens (n 5 22) which had lost
their inhibitory activity after storage were found on subsequent
urinalysis to have retained the implicated inhibitory substance.
Not all urine specimens were retested by urinalysis. For the 11
urine specimens that were inhibitory in two NAA assays, we
attempted to determine whether one assay was more sensitive
to a single substance, i.e., nitrites. One urine specimen containing nitrites and beta-HCG was inhibitory for TMA and
PCR but not for LCR. Since nitrites were associated with
inhibition for TMA (OR, 3.57) and LCR (OR, 14.36) by multivariate logistic regression analysis and this urine specimen
was not inhibitory for LCR, the existence of a complex interaction between urinary substances resulting in amplification
inhibition is suggested.
Overnight storage at either 4 or 270°C removed 42.1 and
55.5% of the inhibitors for PCR and LCR, respectively, and
79.1% of the inhibitors for TMA. Storage at either 4 or 270°C
combined with dilution to 1:10 removed all of the inhibitors for
LCR and most of the inhibitors for PCR (16 of 19) and TMA
(22 of 24). Phenol-chloroform extraction removed inhibitors
from all urine specimens. The mechanism(s) involved in the
removal of amplification inhibitors following storage at 4 or
270°C and dilution remain unknown. Dilution alone may remove inhibitory activity. Alternatively, freezing and thawing
may destroy labile inhibitory molecules or release additional
target DNA molecules by disrupting microbial cells more efficiently. This might account for the increased sensitivity ob-
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served with the AMPLICOR CT/NG test when frozen specimens are assayed (16). Alternatively, freezing and thawing may
act directly on labile proteinaceous inhibitors, inducing conformational changes and the subsequent loss of inhibitory activity. Salts, especially those containing divalent cations, particularly Mg21 ions, which have a significant effect on the
activity of Taq polymerase, could explain the inhibitory activity
of urinary crystals for PCR and LCR.
In summary, we have demonstrated a variable rate of inhibition for C. trachomatis NAA assays ranging from 3.9 to
11.9%. An elevated rate of inhibition related to pregnancy was
found for PCR but not LCR or TMA. In this study none of the
inhibitory urine specimens were from infected patients, and
the 15 urine specimens with endogenous C. trachomatis nucleic
acid had no inhibitors. Most but not all of the inhibition was
removed by storage and dilution, and only five urine specimens
(three for PCR and two for TMA) required phenol-chloroform
extraction to remove the inhibitors. The use of storage and
dilution of urine specimens should be considered to reduce the
inhibitory effects of urine specimens, especially those to be
tested by PCR or TMA. Alternatively, tests most significantly
affected by urinary inhibitors may benefit from the use of an
internal positive control which gives a signal just above the
positive cutoff value. More studies are warranted to determine
whether urinary factors could be predictive of NAA inhibition.
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